Quarterly report pursuant to Section 13 or 15(d)

Licensing and Other Arrangements - Novartis - VPM087 (Details)

v3.23.2
Licensing and Other Arrangements - Novartis - VPM087 (Details)
$ / shares in Units, $ in Thousands, € in Millions
 3 Months Ended 6 Months Ended
Aug. 24, 2017
USD ($)
agreement
item
$ / shares
shares
Aug. 24, 2017
EUR (€)
agreement
item
shares
Jun. 30, 2023
USD ($)
$ / shares
Jun. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
$ / shares
Jun. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Licensing and other arrangements              
Revenue from contracts with customers     $ 1,125 $ 525 $ 1,125 $ 3,275  
Common Stock              
Licensing and other arrangements              
Stock price (in dollars per share) | $ / shares     $ 18.89   $ 18.89    
Novartis Pharma AG | Gevokizumab License Agreement and IL-1 Target License Agreement              
Licensing and other arrangements              
Transaction price $ 40,200            
Cash payment received 25,700            
License agreement consideration received, repayment of debt 14,300            
Common stock premium $ 200            
Number of license agreements | agreement 2 2          
Number of arrangements | item 1 1          
Number of performance obligations | item 2 2          
Remaining performance obligations     $ 0   $ 0    
Revenue from contracts with customers $ 40,200   0 $ 0 0 $ 0  
Contract assets     0   0   $ 0
Contract liabilities     0   0   0
Capitalized contract costs     $ 0   $ 0   $ 0
Novartis Pharma AG | Gevokizumab License Agreement              
Licensing and other arrangements              
License agreement consideration received 30,000            
Cash payment received 15,700            
License agreement consideration received, repayment of debt 14,300 € 12.0          
Proceeds from issuance of common stock 5,000            
Common stock premium 200            
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones $ 438,000            
Agreement termination prior written notice period 6 months 6 months          
Novartis Pharma AG | Gevokizumab License Agreement | Common Stock              
Licensing and other arrangements              
Shares issued (in shares) | shares 539,131 539,131          
Purchase price (in dollars per share) | $ / shares $ 9.2742            
Issuance of common stock, fair value $ 4,800            
Stock price (in dollars per share) | $ / shares $ 8.93            
Novartis Pharma AG | IL-1 Target License Agreement              
Licensing and other arrangements              
Cash payment received $ 10,000